

CARD *In Situ* Hybridization: Sights and Signals

Ernst J. M. Speel and Paul Komminoth

Abstract

During the last decade, several strategies have been developed to improve the detection sensitivity of *in situ* hybridization (ISH) by amplification of either target nucleic acid sequences prior to ISH (e.g., *in situ* PCR), or the detection signals after the hybridization procedures (signal amplification). Here we outline the principles of tyramide signal amplification using the catalyzed reporter deposition (CARD) technique, summarize applications as well as possible limitations of CARD ISH, and discuss some future directions of *in situ* nucleic acid detection using this amplification strategy.

Key Words: *In situ* hybridization; tyromide; signal amplification; mRNA; DNA; catalyzed reporter deposition; interphase cytogenetics.

Introduction

In situ hybridization (ISH) is now an established molecular tool in research and diagnostics and has significantly advanced the study of gene structure and expression at the level of individual cells. Currently, the technique provides an optimal detection sensitivity of approx 1 kb of target DNA in cell preparations using fluorescence approaches in combination with charge-coupled device (CCD) recordings and image analysis [1]. The ultimate mRNA detection limit, however, is more difficult to determine but may reach the level of single mRNA molecules in the most optimal test systems [2]. For detection of nucleic acid sequences in routinely processed tissue sections of paraffin-embedded specimens, these sensitivities may not be reached. As a consequence, ISH detection limits on tissue sections are rather in the range of 40 kb of target DNA and 10–20 copies of mRNA or viral DNA per cell [3–6].

In recent years, several strategies have been developed to improve the sensitivity of ISH. These include the use of increased absolute amounts of hybridized probes (cocktails of oligonucleotides or multiple cRNA probes) [7] and the amplification of either nucleic acid targets (target amplification) [8,9] or of (immuno) cytochemical detection signals (signal amplification) *in situ* [10,11].

In general, target amplification methods combine polymerase chain reaction (PCR) and ISH to visualize specific amplified DNA and RNA sequences within cell and tissue preparations. Theoretically these *in situ* PCR techniques are straightforward, but in practice they are hampered by several obstacles, such as low amplification efficiency (restricted sensitivity), poor reproducibility (restricted specificity), and difficulties in quantification of the results [12–15]. As a consequence, other approaches to increase the sensitivity of ISH have been explored, of which

Department of Pathology
University of Zurich,
Schmelzbergstrasse 12,
CH-8091 Zurich, Switzerland

Address correspondence to
Ernst J. M. Speel, Ph.D.
Department of Pathology,
University of Zurich,
Schmelzbergstrasse 12,
CH-8091 Zurich, Switzerland.
E-mail: ernst-jom.speel@pty.usz.ch

Endocrine Pathology, vol. 10,
no. 3, 193–198, Fall 1999
© Copyright 1999 by Humana
Press Inc. All rights of any
nature whatsoever reserved.
1046-3976/99/10:193-198/\$11.50




Fig. 1. Principles of CARD signal amplification for ISH. (A) Hybridization *in situ* with a hapten-labeled probe. (B) Application of a one-step (anti-hapten antibody conjugated to horseradish peroxidase; B₁), two-step (anti-hapten antibody and a horseradish peroxidase labeled secondary antibody; B₂), or three-step (avidin-biotin horseradish peroxidase complex; B₃) probe detection system. (C) Production of haptenized tyramide radicals by horseradish peroxidase catalyzed CARD signal amplification. (D) Deposition of tyramide radicals to tyrosine moieties of proteins *in situ* in the vicinity of hybridization. Direct visualization of fluorochrome-labeled tyramides and indirect visualization of hapten-labeled tyramides with anti-hapten antibody or (strept)avidin conjugates labeled with fluorochromes or enzymes.

the CARD signal amplification method appears to be the most promising.

Principles of CARD Signal Amplification

The method of CARD signal amplification has been developed by Bobrow et al. [16] for use in immuno-blotting and ELISA assays and is based on the deposition of a large number of haptenized tyramide molecules promoted by peroxidase activity (Fig. 1). Tyramine is a phenolic compound and horseradish peroxidase (HRP) can catalyze the dimerization of such compounds when they are present at high concentrations probably by the generation of free radical intermediates. If

applied in lower concentrations, such as used in the signal amplification reaction, the probability of tyramine dimerization is reduced, whereas the binding of the highly reactive intermediates to electron-rich moieties of proteins, such as tyrosine, at or near the site of the peroxidase binding site is favored. In this way, many hapten-labeled tyramine molecules (tyramides) can be deposited at the hybridization site *in situ*. Visualization of deposited tyramides can be performed either directly after the CARD reaction with fluorescence microscopy, if fluorochrome-labeled tyramides are used, or indirectly with either fluorescence or brightfield microscopy, if biotin, digoxigenin, di- or trinitrophenyl are used as haptens, which can act as further binding sites for anti-hapten antibody-

ies or (strept)avidin conjugates (in the case of biotinylated tyramides) [3]. Also fluorescein and rhodamin can be used as haptens, since specific antibodies against these fluorochromes are commercially available from several companies.

Applications and Limitations of CARD Signal Amplification

CARD signal amplification with biotinylated tyramides has been adapted for immunohistochemistry by Adams [17], allowing an increase in sensitivity of up to 1000-fold when compared with conventional avidin biotinylated enzyme complex (ABC) procedures [17–21]. In these studies, the amplification factor was assessed by determining the maximal dilution of the primary antibody leading still to identical staining results as compared with standard reactions. In most cases, however, the increase in sensitivity seems to be rather in the range of 50–100-fold, and sometimes even less. As a consequence of this variability the optimal dilution for every primary antibody needs to be determined. CARD signal amplification has also been applied to visualize antigens or incorporated BrdU in fluorescence microscopy [22,23] or electron microscopy [24,25], and has further been used for double staining with two unconjugated primary antisera raised in the same species [26].

Since 1995, CARD has further been implemented in detection procedures of both DNA and RNA ISH on cell preparations and tissue sections. With signal amplification, the ISH sensitivity could be improved in the range of 2- to 100-fold, enabling the detection of up to three different repetitive and single-copy (1–5 kb) DNA sequences in the same cell [22,27–30] as well as low copy viral RNA [31,32] and mRNA ranging from high to low

abundancy in cell and tissue preparations [10,33–36].

As an example of the diagnostic potential of CARD ISH, we have implemented CARD signal amplification for our diagnostic nonradioactive oligonucleotide ISH procedure in order to increase the sensitivity of the assay and to shorten its overall turnaround-time [10,33]. This approach allows, e.g., the detection of peptide hormone mRNA in tissue sections from routinely fixed, paraffin-embedded surgical samples within one working day and makes the assay suitable for routine diagnostic purposes. Furthermore, it allows the use of diaminobenzidine (DAB) as a chromogen and, as a consequence, the application of conventional counterstains and the mounting of slides in xylene-based mounting solutions, making the procedure more acceptable to perform in a diagnostic setting.

To date, most of the protocols still use biotinylated tyramides for the amplification step, which can easily be obtained commercially (e.g., NEN Life Science Products, Boston, MA and Dako, Glostrup, Denmark) or synthesized in the laboratory [16,17,27,28,30,37]. However, similar to immunohistochemical procedures, the use of biotin is associated with significant disadvantages, especially when working with tissue sections. Thus, in tissues with high amounts of endogenous biotin, such as liver or kidney, a low signal-to-noise ratio due to high background staining may be encountered. It is therefore desirable to be able to rely on differently labeled tyramides, e.g., with digoxigenin, di- or trinitriphenyl [10,30,33], or fluorochromes [10,22,30,33,34], which is now possible. These tyramide conjugates can also be used in multiple-target ISH approaches [22,29,30] or the combination of immunohistochemistry and ISH with signal amplification.

Although the increase in ISH sensitivity by using CARD signal amplification is obvious from the literature, speculation about the obtained amplification factor is difficult. Moreover, since the tyramide deposition reaction runs very quickly, minor differences in amplification reaction time may lead to variations in the final signal intensities. Nevertheless, an amplification factor in the range of 5- to 10-fold, or possibly higher, together with preservation of distinct localization of ISH signals seems to be a realistic indication for both DNA and mRNA ISH.

Since with CARD signal amplification both specific and nonspecific (background) ISH signals will be amplified, it is essential that nonspecific probe binding and detection have to be avoided in order to successfully apply this procedure [22,30,35,36]. Therefore, we recommend that one should always optimize probe hybridization and cytochemical probe detection when applying CARD signal amplification in order to achieve discretely localized ISH signals of high intensity. In our hands, the number of cytochemical detection layers (e.g., one layer is sufficient for repetitive, centromeric DNA detection but minimal two layers are recommended for DNA targets of 40 kb), the dilution of detection conjugates (usually the first detection layer can be diluted 2–10-fold further than in conventional detection systems), the tyramide concentration in the CARD amplification buffer (usually concentrations in the range of 2–12 μ M are used [30]), and the reaction time (usually 5–15 min at room temperature or 37°C) are the most important parameters to consider.

Conclusions

CARD signal amplification using labeled tyramides is an easy-to-perform,

fast, highly sensitive, and efficient procedure to increase the detection sensitivity of ISH and immunohistochemistry and appears to become the method of choice for diagnostic laboratories. It will not only promote the detection of viral or mRNA but also facilitate the evaluation of chromosomal aberrations in cytological and histological specimens. Furthermore, it might also help to advance the development of automated ISH spot-counting by computer-assisted image generation and analysis. The now available spectrum of probe labels, detection systems, and tyramide conjugates for CARD signal amplification will further improve the applicability and sensitivity of ISH as well as promote multiple-target nucleic acid detection in situ and procedures combining ISH and immunophenotyping [38].

Acknowledgments

The authors thank P. Saremaslani for excellent technical assistance, N. Wey for computer-assisted reproductions, and A.H.N. Hopman, F.C.S. Ramaekers, J. Roth, and Ph.U. Heitz for continuous support.

References

1. Lichter P, Bentz M, Joos S. Detection of chromosomal aberrations by means of molecular cytogenetics: Painting of chromosomes and chromosomal subregions and comparative genomic hybridization. In: Vogt P, IM Verma, eds. *Oncogene techniques*. San Diego, CA: Academic Press, 334–359, 1995.
2. Femino AM, Fay FS, Fogarty K, Singer RH. Visualization of single RNA transcripts in situ. *Science* 280:585–590, 1998.
3. Speel EJM, Ramaekers FC, Hopman AHN. Cytochemical detection systems for in situ hybridization, and the combination with immunocytochemistry. "Who is still afraid of red, green and blue?" *Histochem J* 27:833–858, 1995.

4. Höfler H, Childers H, Montminy MR, Lechan RM, Goodman RH, Wolfe HJ. In situ hybridization methods for the detection of somatostatin mRNA in tissue sections using antisense RNA probes. *Histochem J* 18:597–604, 1986.
5. Dirks RW. RNA molecules lighting up under the microscope. *Histochem Cell Biol* 106: 151–166, 1996.
6. McNicol AM, Farquharson MA. In situ hybridization and its diagnostic applications in pathology. *J Pathol* 182: 250–61, 1997.
7. Trembleau A, Bloom FE. Enhanced sensitivity for light and electron microscopic in situ hybridization with multiple simultaneous non-radioactive oligodeoxynucleotide probes. *J Histochem Cytochem* 43:829–841, 1995.
8. Komminoth P, Long AA. In situ polymerase chain reaction and its applications to the study of endocrine diseases. *Endocr Pathol* 6:167–171, 1995.
9. Long AA, Komminoth P. In situ polymerase chain reaction: an overview. In: Gosden JR, eds. *Methods in Molecular Biology Vol. 71. PRINS and in situ PCR Protocols*. Totowa NJ: Humana Press Inc., 141–161, 1997.
10. Speel EJM, Hopman AHN, Komminoth P. Signal amplification for DNA and mRNA in situ hybridization. In: Darby J, eds. *In situ hybridization protocols*. Totowa: Humana Press, 2000.
11. Komminoth P, Werner M. Target and signal amplification: approaches to increase the sensitivity of in situ hybridization. *Histochem Cell Biol* 108: 325–333, 1997.
12. Long AA, Komminoth P, Lee E, Wolfe HJ. Comparison of indirect and direct in-situ polymerase chain reaction in cell preparations and tissue sections. Detection of viral DNA, gene rearrangements and chromosomal translocations. *Histochemistry* 99:151–162, 1993.
13. Komminoth P, Long AA. In-situ polymerase chain reaction. An overview of methods, applications and limitations of a new molecular technique. *Virchows Arch B* 64:67–73, 1993.
14. Komminoth P, Adams V, Long AA, Roth J, Saremaslani P, Flury R, Schmid M, Heitz PU. Evaluation of methods for hepatitis C virus (HCV) detection in liver biopsies: comparison of histology, immunohistochemistry, in-situ hybridization, reverse transcriptase (RT) PCR and in-situ RT PCR. *Path Res Pract* 190:1017–1025, 1994.
15. Höfler H. In situ polymerase chain reaction: toy or tool? (Editorial). *Histochemistry* 99:103–104, 1993.
16. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. *J Immunol Methods* 125:279–285, 1989.
17. Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. *J Histochem Cytochem* 40:1457–1463, 1992.
18. Berghorn KA, Bonnett JH, Hoffman GE. cFos immunoreactivity is enhanced with biotin amplification. *J Histochem Cytochem* 42:1635–1642, 1994.
19. Merz H, Malisius R, Mannweiler S, Zhou R, Hartmann W, Orscheschek K, Moubayed P, Feller AC. ImmunoMax. A maximized immunohistochemical method for the retrieval and enhancement of hidden antigens. *Lab Invest* 73:149–156, 1995.
20. Sanno N, Teramoto A, Sugiyama M, Itoh Y, Osamura RY. Application of catalyzed signal amplification in immunodetection of gonadotropin subunits in clinically nonfunctioning pituitary adenomas. *Am J Clin Pathol* 106:16–21, 1996.
21. Werner M, von Waasielewski R, Komminoth P. Antigen retrieval, signal amplification and intensification in immunohistochemistry. *Histochem Cell Biol* 105:253–260, 1996.
22. van Gijlswijk RPM, Zijlmans HJ, Wiegant J, Bobrow MN, Erickson TJ, Adler KE, Tanke HJ, Raap AK. Fluorochrome-labeled tyramides: use in immunocytochemistry and fluorescence in situ hybridization. *J Histochem Cytochem* 45:375–382, 1997.
23. Van Heusden J, de Jong P, Ramaekers F, Bruwier H, Borgers M, Smets G. Fluorescein-labeled tyramide strongly enhances the detection of low bromodeoxyuridine incorporation levels. *J Histochem Cytochem* 45:315–319, 1997.
24. Schöfer C, Weipoltshammer K, Almeder M, Wachtler F. Signal amplification at the ultrastructural level using biotinylated tyramides and immunogold detection. *Histochem Cell Biol* 108:313–319, 1997.
25. Mayer G, Bendayan M. Biotinyl-tyramide: a novel approach for electron microscopic immunocytochemistry. *J Histochem Cytochem* 45:1449–1454, 1997.

26. Shindler KS, Roth KA. Double immunofluorescent staining using two unconjugated primary antisera raised in the same species. *J Histochem Cytochem* 44:1331-1335, 1996.
27. Kerstens HM, Poddighe PJ, Hanselaar AG. A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine. *J Histochem Cytochem* 43:347-352, 1995.
28. Raap AK, Van de Corput MPC, Vervenne RAW, van Gijlswijk RPM, Tanke HJ, Wiegant J. Ultra-sensitive FISH using peroxidase-mediated deposition of biotin- or fluorochrome tyramides. *Hum Mol Genet* 4:529-534, 1995.
29. Speel EJM, Ramaekers FCS, Hopman AHN. Sensitive multicolor fluorescence in situ hybridization using catalyzed reporter deposition (CARD) amplification. *J Histochem Cytochem* 45:1439-1446, 1997.
30. Hopman AHN, Ramaekers FCS, Speel EJM. Rapid synthesis of biotin-, digoxigenin-, trinitrophenyl-, and fluorochrome-labeled tyramides and their application for in situ hybridization using CARD-amplification. *J Histochem Cytochem* 46:771-777, 1998.
31. Adler K, Erickson T, Bobrow M. High sensitivity detection of HPV-16 in SiHa and CaSki cells utilizing FISH enhanced by TSA. *Histochem Cell Biol* 108:321-324, 1997.
32. Reed JA, Nador RG, Spaulding D, Tani Y, Cesarman E, Knowles DM. Demonstration of Kaposi's sarcoma-associated herpes virus cyclin D homolog in cutaneous Kaposi's sarcoma by colorimetric in situ hybridization using a catalyzed signal amplification system. *Blood* 91:3825-3832, 1998.
33. Speel EJM, Saremaslani P, Roth J, Hopman AHN, Komminoth P. Improved mRNA in situ hybridization on formaldehyde-fixed and paraffin-embedded tissue using signal amplification with different haptenized tyramides. *Histochem Cell Biol* 110:571-577, 1998.
34. Schmidt BF, Chao J, Zhu Z, DeBiasio RL, Fisher G. Signal amplification in the detection of single-copy DNA and RNA by enzyme-catalyzed deposition (CARD) of the novel fluorescent reporter substrate Cy3.29-tyramide. *J Histochem Cytochem* 45:365-373, 1997.
35. Van de Corput MPC, Dirks RW, Van Gijlswijk RPM, Van Binnendijk E, Hattinger CM, De Paus RA, Landegent JE, Raap AK. Sensitive mRNA detection by fluorescence in situ hybridization using horseradish peroxidase-labeled oligodeoxynucleotides and tyramide signal amplification. *J Histochem Cytochem* 46:1249-1259, 1998.
36. Yang H, Wanner IB, Roper SD, Chaudhari N. An optimized method for in situ hybridization with signal amplification that allows the detection of rare mRNAs. *J Histochem Cytochem* 47:431-445, 1999.
37. Jacobs W, Dhaene K, VanMarck E. Tyramine-amplified immunohistochemical testing using "homemade" biotinylated tyramine is highly sensitive and cost-effective. *Archives of Pathology and Laboratory Medicine* 122: 642-643, 1998.
38. Speel EJM. Detection and amplification systems for sensitive, multiple-target DNA and RNA in situ hybridization: looking inside cells with a spectrum of colors. *Histochem Cell Biol* 112:89-113, 1999.